3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
36
Neoplasm Metastasis
8
Ovarian Neoplasms
5
Sarcoma
4
Neoplasms
4
Lymphoma, Non-Hodgkin
4
Pancreatic Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Glioma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Medulloblastoma
2
Lymphoma, Mantle-Cell
2
Lung Neoplasms
2
Liposarcoma
2
Histiocytosis, Langerhans-Cell
2
Hereditary Sensory and Autonomic Neuropathies
2
Interventions
ribociclib
1
palbociclib
1
exemestane
1
abemaciclib
1
Letrozole
1
Fulvestrant
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unilateral Breast Neoplasms
×
palbociclib
×
90 days
×
Clear all
NCT06760637
2026-05-19
FourLight-3
Pfizer
Phase 3
Active not recruiting
1,035 enrolled